Singapore pharma firms seek clarity on US tariff exemption, deputy PM says

ReutersSep 27, 2025 6:30 AM

View all comments（0）



KUALA LUMPUR, Sept 27 (Reuters) - Pharmaceutical companies in Singapore are seeking clarity on whether they would qualify for an exemption from steep tariffs imposed by the United States on their goods, Deputy Prime Minister Gan Kim Yong said on Saturday.

Many of the firms have plans to expand or build their business footprint in the United States, which may qualify them for a tariff exemption, Gan, who is also trade minister, told reporters.

President Donald Trump on Thursday unveiled fresh tariffs on imported goods, including 100% duties on patented drugs.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Japan and South Korea Stocks Open Lower, Samsung Strike Storm and Higher-Than-Expected Inflation Disrupt Markets

TradingKey - On May 13, the Nikkei 225 Index opened 0.5% lower, while South Korea’s KOSPI Index opened down 1.7% before losses further widened to 3%.

Today’s Market Recap: US Inflation Hits 3-Year Peak as Market Braces for Trump’s China Visit and Fed Leadership Shift

April inflation hit a three-year peak of 3.8%, pressuring the Nasdaq and tech stocks. Markets are further braced by Kevin Warsh’s Fed Chair confirmation, the maintenance of Trump’s 10% global tariffs, and a high-profile U.S. business delegation preparing for a strategic state visit to China.

BigBear.ai Stock Down 26% YTD – Should You Invest in BBAI Stock in 2026? Can the Ask Sage Deal Lead to a Rebound?

TradingKey - BigBear.ai (BBAI) provided a modest first-quarter update on May 5, and BBAI shares have declined about 26% year to date. The company finalized the acquisition of Ask Sage in January, marking its shift away from a services-heavy government contractor to a platform-centric AI company. The

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

TradingKey - On May 5 (ET), Advanced Micro Devices (AMD) released its first-quarter fiscal 2026 financial results after the market close. The company reported revenue of $10.253 billion, up 38% year-over-year, exceeding market expectations of $9.89 billion. Non-GAAP earnings per share (EPS) were $1.

Featured Tools